Viewing Protocol Section

Home Icon Home Search Icon Search Alerts Icon Stocks Certify Doc Icon Certify Doc Certify Doc Icon Genes Certify Doc Icon Clinical Trials Certify Doc Icon CompTox Processes Icon DrugMatrix Open Targets Icon Open Targets Processes Icon Products Support Icon Support Bugs Icon Bugs eRecord Icon eRecord
Main Search All Studies All Organizations Report Bug
Viewing Protocol Section

Thank You for evaluating our software.

Clinical Trials

To give you an idea of how we make custom software. We have taken all of the Clinical Trials Information from our Federal Government(https://clinicaltrials.gov/).

The JSON File Structure of the files is as follows: Full Study -> Study => Sections => Modules. You are currently viewing a Protocol Section and its Modules.

We give the table structure here to give you an idea of what you are looking at. We put the explanation to the left and the data to the right.

A Protocol Section has the following Modules.

1. Identification Module

2. Status Module

3. Sponsor Collaborators Module

4. Oversight Module

5. Description Module

6. Conditions Module

7. Design Module

8. Arms Interventions Module

9. Outcomes Module

10. Eligibility Module

11. Contacts Locations Module

12. References Module

13. IPD Sharing Statement Module

Viewing Protocol Section

Study NCT00003934
Ignite Creation Date: 2024-05-05 @ 10:17 AM
Last Modification Date: 2024-10-26 @ 9:04 AM
Study NCT ID: NCT00003934
Protocol Section: NCT00003934
Start Identification Module Data
Expand Identification Module Data
Brief Title: Tretinoin Cytarabine and Daunorubicin Hydrochloride With or Without Arsenic Trioxide Followed by Tretinoin With or Without Mercaptopurine and Methotrexate in Treating Patients With Acute Promyelocytic Leukemia
Official Title: Phase III Randomized Study of Concurrent Tretinoin and Chemotherapy With or Without Arsenic Trioxide AS2O3 NSC 706363 as Initial Consolidation Therapy Followed by Maintenance Therapy With Intermittent Tretinoin Versus Intermittent Tretinoin Plus Mercaptopurine and Methotrexate for Patients With Untreated Acute Promyelocytic Leukemia
Acronym: None
Organization: National Cancer Institute NCI
Organization Class: NIH
Organization Study ID: NCI-2012-02811
Secondary IDs
Secondary ID Type Domain Link
U10CA031946 NIH None httpsreporternihgovquickSearchU10CA031946
C9710 None None None
CDR0000067126 None None None
CALGB-C9710 None None None
Start Status Module Data
Status Verified Date: 2013-06
Overall Status: COMPLETED
Study First Submit Date:
Study First Submit QC Date:
Last Update Submit Date:
Status:
Start Sponsor Collaborators Module Data
Investigator:
Lead Sponsor: National Cancer Institute NCI
Lead Sponsor Class: NIH
Lead Sponsor: National Cancer Institute NCI
Start Oversight Module Data
Description Module:
Study Last Update Post Date Type(Status Module):
Attachment: Upload